Home › Companies › Kymera Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Kymera Therapeutics, Inc.’s Form 8-K, filed June 24, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 24, 2026: 6 items on Kymera Therapeutics, Inc.’s Form 8-K, filed June 24, 2026: 2 approved · 4 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Kymera Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Kymera Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bruce Booth, D.Phil. | 71,962,459 | -- | -- | 5,430,527 | 1,707,176 | 93% | Not verified | — |
| Elect Director: Nello Mainolfi, Ph.D. | 73,411,316 | -- | -- | 3,981,670 | 1,707,176 | 95% | Not verified | — |
| Elect Director: John Maraganore, Ph.D. | 72,501,958 | -- | -- | 4,891,028 | 1,707,176 | 94% | Not verified | — |
| Elect Director: Elena Ridloff, CFA | 72,453,404 | -- | -- | 4,939,582 | 1,707,176 | 94% | Not verified | — |
| 2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers | 74,903,687 | 2,462,732 | 26,567 | -- | 1,707,176 | 97% | Approved | — |
| 3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 79,043,801 | 38,128 | 18,233 | -- | 0 | 99.9% | Approved | — |
Source: Kymera Therapeutics, Inc., Form 8-K, filed with the SEC on June 24, 2026 — read the filing on EDGAR.
Each item below shows how the 277 asset managers that disclosed a Kymera Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.
Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Bruce Booth, D.Phil.”): 71,962,459 for, 5,430,527 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 32,651,732 for, 1,280,772 withheld, 276,669 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,165,517 | 0 | 9 | 0 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 1,490,604 | 0 | 0 | 0 | For |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 623,469 | 0 | 0 | 5,342 | For |
| Jackson National | 488,082 | 0 | 73,829 | 0 | Mixed |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 274,851 | 0 | 0 | 0 | For |
| Prudential/PGIM | 222,115 | 0 | 0 | 11,894 | Mixed |
| Dimensional | 0 | 0 | 0 | 228,222 | Withhold |
| Putnam | 226,602 | 0 | 0 | 0 | For |
| State Street | 440 | 0 | 0 | 218,757 | Withhold |
| Equitable | 218,570 | 0 | 0 | 0 | For |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 204,255 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 186,016 | 0 | 0 | 0 | For |
| Voya | 173,983 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 170,127 | Withhold |
| Bridge Builder Trust | 10,910 | 0 | 118,038 | 0 | Mixed |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,281 | 0 | 0 | 65,357 | Mixed |
| PENN SERIES FUNDS INC | 99,000 | 0 | 0 | 1,500 | For |
| Victory Capital | 509 | 0 | 0 | 99,122 | Withhold |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
Combines 8 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFA
Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Elena Ridloff, CFA”): 72,453,404 for, 4,939,582 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 32,300,401 for, 1,632,103 withheld, 276,669 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,162,065 | 0 | 9 | 3,452 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 1,490,604 | 0 | 0 | 0 | For |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 623,469 | 0 | 0 | 5,342 | For |
| Jackson National | 488,082 | 0 | 73,829 | 0 | Mixed |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 274,851 | Withhold |
| Prudential/PGIM | 222,115 | 0 | 0 | 11,894 | Mixed |
| Dimensional | 0 | 0 | 0 | 228,222 | Withhold |
| Putnam | 226,602 | 0 | 0 | 0 | For |
| State Street | 218,939 | 0 | 0 | 258 | For |
| Equitable | 102,594 | 0 | 0 | 115,976 | Mixed |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 204,255 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 186,016 | Withhold |
| Voya | 173,983 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 170,127 | Withhold |
| Bridge Builder Trust | 10,910 | 0 | 118,038 | 0 | Mixed |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,281 | 0 | 0 | 27,357 | Mixed |
| PENN SERIES FUNDS INC | 100,500 | 0 | 0 | 0 | For |
| Victory Capital | 509 | 0 | 0 | 99,122 | Withhold |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
Combines 8 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Maraganore, Ph.D.
Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 72,501,958 for, 4,891,028 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 32,408,466 for, 1,524,039 withheld, 276,668 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,165,518 | 0 | 8 | 0 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 1,490,604 | 0 | 0 | 0 | For |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 623,469 | 0 | 0 | 5,342 | For |
| Jackson National | 488,082 | 0 | 73,829 | 0 | Mixed |
| Federated Hermes | 0 | 0 | 0 | 536,680 | Withhold |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 274,851 | 0 | 0 | 0 | For |
| Prudential/PGIM | 222,115 | 0 | 0 | 11,894 | Mixed |
| Dimensional | 0 | 0 | 0 | 228,222 | Withhold |
| Putnam | 226,602 | 0 | 0 | 0 | For |
| State Street | 218,939 | 0 | 0 | 258 | For |
| Equitable | 218,570 | 0 | 0 | 0 | For |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 204,255 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 186,016 | 0 | 0 | 0 | For |
| Voya | 173,983 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 170,127 | Withhold |
| Bridge Builder Trust | 10,910 | 0 | 118,038 | 0 | Mixed |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,281 | 0 | 0 | 27,357 | Mixed |
| PENN SERIES FUNDS INC | 100,500 | 0 | 0 | 0 | For |
| Victory Capital | 509 | 0 | 0 | 99,122 | Withhold |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
Combines 8 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Nello Mainolfi, Ph.D.
Kymera Therapeutics, Inc.’s own tally for this item (“Elect Director: Nello Mainolfi, Ph.D.”): 73,411,316 for, 3,981,670 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 32,975,419 for, 957,087 withheld, 276,667 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,165,519 | 0 | 7 | 0 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 1,490,604 | 0 | 0 | 0 | For |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 623,469 | 0 | 0 | 5,342 | For |
| Jackson National | 488,082 | 0 | 73,829 | 0 | Mixed |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 274,851 | 0 | 0 | 0 | For |
| Prudential/PGIM | 222,115 | 0 | 0 | 11,894 | Mixed |
| Dimensional | 0 | 0 | 0 | 228,222 | Withhold |
| Putnam | 226,602 | 0 | 0 | 0 | For |
| State Street | 218,939 | 0 | 0 | 258 | For |
| Equitable | 218,570 | 0 | 0 | 0 | For |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 204,255 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 186,016 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 173,983 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 170,127 | Withhold |
| Bridge Builder Trust | 10,910 | 0 | 118,038 | 0 | Mixed |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 84,281 | 0 | 0 | 27,357 | Mixed |
| PENN SERIES FUNDS INC | 100,500 | 0 | 0 | 0 | For |
| Victory Capital | 509 | 0 | 0 | 99,122 | Withhold |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
Combines 8 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers; and
Kymera Therapeutics, Inc.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 74,903,687 for, 2,462,732 against — passed, per its Form 8-K filed June 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,165,524 | 1 | 0 | 0 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,490,604 | 0 | 0 | Against |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 628,811 | 0 | 0 | 0 | For |
| Jackson National | 561,911 | 0 | 0 | 0 | For |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 274,851 | 0 | 0 | 0 | For |
| Putnam | 235,642 | 0 | 0 | 0 | For |
| Prudential/PGIM | 234,009 | 0 | 0 | 0 | For |
| Dimensional | 228,222 | 0 | 0 | 0 | For |
| State Street | 219,113 | 84 | 0 | 0 | For |
| Equitable | 218,570 | 0 | 0 | 0 | For |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 204,255 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 186,016 | 0 | 0 | 0 | For |
| Voya | 173,983 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 170,127 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 128,948 | 0 | 0 | 0 | For |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 111,638 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 100,500 | 0 | 0 | 0 | For |
| Victory Capital | 99,631 | 0 | 0 | 0 | For |
Fund voting reports, all 84 managers: 32,675,290 for, 1,501,647 against, 17,732 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,531,407 | 0 | 0 | 0 | For |
| T. Rowe Price | 11,245,894 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 8,657,242 | 0 | 0 | 0 | For |
| BVF INC/IL | 5,502,710 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 4,411,361 | 0 | 0 | 0 | For |
| Wellington | 3,421,111 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 3,398,093 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,986,830 | 0 | 0 | 0 | For |
| BlackRock | 1,691,359 | 8,838 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,575,171 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,490,604 | 0 | 0 | Against |
| State Street | 861,358 | 84 | 0 | 0 | For |
| AllianceBernstein | 828,448 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 565,103 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 561,170 | 0 | 0 | 0 | For |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Vanguard | 516,651 | 0 | 0 | 0 | For |
| Charles Schwab | 500,560 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 468,500 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 437,897 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 407,050 | 0 | 0 | 0 | For |
| Putnam | 349,791 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 309,479 | 0 | 0 | 0 | For |
| Northern Trust | 273,585 | 4,066 | 0 | 0 | For |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 265,697 | 0 | 0 | 0 | For |
Institutional-manager reports, all 217 managers: 64,601,846 for, 2,275,865 against, 1,277 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Kymera Therapeutics, Inc.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 79,043,801 for, 38,128 against — passed, per its Form 8-K filed June 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 34,209,514 for, 6 against, 17,732 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,386,510 | 0 | 0 | 0 | For |
| Vanguard | 8,165,526 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,712,301 | 0 | 0 | 0 | For |
| Capital Group | 1,490,604 | 0 | 0 | 0 | For |
| BlackRock | 1,277,036 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 628,811 | 0 | 0 | 0 | For |
| Jackson National | 561,911 | 0 | 0 | 0 | For |
| Federated Hermes | 536,680 | 0 | 0 | 0 | For |
| Charles Schwab | 496,084 | 0 | 0 | 0 | For |
| AllianceBernstein | 274,851 | 0 | 0 | 0 | For |
| Putnam | 235,642 | 0 | 0 | 0 | For |
| Prudential/PGIM | 234,009 | 0 | 0 | 0 | For |
| Dimensional | 228,222 | 0 | 0 | 0 | For |
| State Street | 219,191 | 6 | 0 | 0 | For |
| Equitable | 218,570 | 0 | 0 | 0 | For |
| Hartford | 210,901 | 0 | 0 | 0 | For |
| MFS | 204,255 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 186,016 | 0 | 0 | 0 | For |
| Voya | 173,983 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 170,127 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 128,948 | 0 | 0 | 0 | For |
| TIAA | 118,801 | 0 | 0 | 0 | For |
| Lincoln Financial | 111,638 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 100,500 | 0 | 0 | 0 | For |
| Victory Capital | 99,631 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,257,588 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.41% |
| 2 | Vanguard | 9.93% |
| 3 | T. Rowe Price | 9.38% |
| 4 | Capital Group | 1.81% |
| 5 | BlackRock | 1.55% |
| 6 | MUTUAL FUND SERIES TRUST | 0.76% |
| 7 | Jackson National | 0.68% |
| 8 | Federated Hermes | 0.65% |
| 9 | Charles Schwab | 0.60% |
| 10 | AllianceBernstein | 0.33% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.02% |
| 2 | T. Rowe Price | 13.67% |
| 3 | BAKER BROS. ADVISORS LP | 10.52% |
| 4 | BVF INC/IL | 6.69% |
| 5 | Atlas Venture Life Science Advisors, LLC | 5.36% |
| 6 | Wellington | 4.16% |
| 7 | Avoro Capital Advisors LLC | 4.13% |
| 8 | Siren, L.L.C. | 3.63% |
| 9 | BlackRock | 2.07% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.91% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.22% | 13F |
| FMR LLC | 10.85% | DEF14A |
| Entities affiliated with Baker Bros. Advisors LP | 10.55% | DEF14A |
| Felix J. Baker, Ph.D. | 10.55% | DEF14A |
| Avoro Capital Advisors LLC | 9.42% | DEF14A |
| Entities affiliated with BVF Partners L.P. | 8.47% | DEF14A |
| Vanguard Group | 7.62% | 13F |
| T. Rowe Price | 7.37% | 13F |
| BVF PARTNERS L P/IL | 6.37% | 13D |
| Entities affiliated with the Vanguard Group | 6.36% | DEF14A |
Percentages above are of 82,257,588 shares outstanding, as reported by Kymera Therapeutics, Inc. on its Form 10-Q dated April 24, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Kymera Therapeutics, Inc.’s 10-Q dated April 24, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Kymera Therapeutics, Inc.'s shareholder meeting held June 24, 2026, in the 2025-2026 proxy season, 277 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 2,466 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — Kymera Therapeutics, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Kymera Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2026.
Kymera Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.